Search

• 

  Sir Jonathan Symonds CBE

  Company

  Jon was appointed to the Board as Chair on 1 September 2019 with extensive international financial, life sciences and governance experience.

  https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/sir-jonathan-symonds/

  First published: 08 November 2024

• GSK announces regulatory submissions for mepolizumab in severe eosinophilic asthma

  Media

  GSK announced that it has filed regulatory submissions in the USA and Europe for mepolizumab for patients with severe eosinophilic asthma

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-mepolizumab-in-severe-eosinophilic-asthma/

  First published: 05 November 2014

• Results announcement for fourth quarter 2013

  Media

  GSK announces core EPS of 112.2p and dividend of 78p.

  https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-fourth-quarter-2013/

  First published: 05 February 2014

• Regulatory update on divestment of Nimenrix and Mencevax

  Media

  GSK is divesting its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc).

  https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-divestment-of-nimenrix-and-mencevax/

  First published: 22 June 2015

• 

  GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company

  Media

  GSK announces Sir Dave Lewis appointed Non-Executive Chair Designate of independent Consumer Healthcare company

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-sir-dave-lewis-appointed-non-executive-chair-designate-of-independent-consumer-healthcare-company/

  First published: 20 December 2021

• Update on three-part transaction with Novartis

  Media

  GSK today announces good progress on obtaining clearances and approvals to enable completion of its three-part transaction with Novartis

  https://www.gsk.com/en-gb/media/press-releases/update-on-three-part-transaction-with-novartis/

  First published: 25 February 2015

• Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

  Media

  ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion.

  https://www.gsk.com/en-gb/media/press-releases/triumeq-dolutegravirabacavirlamivudine-single-tablet-regimen-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-hiv/

  First published: 27 June 2014

• ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

  Media

  ViiV announced that the FDA has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg), treatment of HIV-1 infection.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-fda-approval-for-triumeq-abacavir-dolutegravir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-1-infection/

  First published: 22 August 2014

• ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

  Media

  ViiV announced, the EC has granted marketing authorisation for Triumeq® for the treatment of HIV in those aged 12+ and weighing 40kg+.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/

  First published: 03 September 2014

• GSK ‘confronts COPD’ to deliver new insights from across the globe to promote improved management of chronic lung disease

  Media

  Data published today suggests, that long-term health outlook for patients with chronic obstructive pulmonary disease (COPD) has improved.

  https://www.gsk.com/en-gb/media/press-releases/gsk-confronts-copd-to-deliver-new-insights-from-across-the-globe-to-promote-improved-management-of-chronic-lung-disease/

  First published: 22 January 2015